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In patients with Cushing’s syndrome, development of 
Pneumocystis pneumonia (PCP) is associated with extreme corti-
sol production levels. In this setting, immune reconstitution after 
abrogation of cortisol excess appears to induce development of 
symptomatic PCP. The high mortality rate warrants timely initi-
ation of chemoprophylaxis or even preemptive treatment of PCP.
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Implementation of prophylaxis guidelines reduced the incidence 
of Pneumocystis pneumonia (PCP) in human immunodefi-
ciency virus (HIV)-infected and transplant recipient popula-
tions over the past decades [1, 2]. However, there is an increasing 
number of patients who develop PCP due to other causes of 
acquired immunodeficiency [3]. Because of deprivation of leu-
kocyte, T-cell, and macrophage function by prolonged exposure 
to supra-physiological levels of cortisol, patients with Cushing’s 
syndrome are at risk of acquiring PCP. The endogenous cortisol 
excess responsible for the clinical phenotype of Cushing’s syn-
drome can be either caused by an adrenocorticotropic hormone 
(ACTH)-producing pituitary adenoma, adrenal adenoma or 
hyperplasia, or ectopic (sometimes malignant) sources of ACTH 
or corticotropin-releasing hormone (CRH) production [4].
The clinical presentation and course of PCP in patients with 
Cushing’s syndrome may differ from patients with PCP due 
to other underlying conditions [5, 6]. Treatment for Cushing’s 
syndrome involves surgical treatment, ie, (1) removal of the 
pituitary or adrenal adenoma or ectopic tumor and/or (2) 
blockage of cortisol production by metyrapone or ketaconazole 
[7]. Thereafter, the functional recovery of immune cells com-
mences [8, 9]. This may subsequently lead to a potent inflam-
matory reaction to Pneumocystis jirovecii in the lungs, resulting 
in a clinical presentation of PCP as an immune reconstitution 
inflammatory syndrome [10]. Because of the very low annual 
incidence of Cushing’s syndrome (approximately 0.2–5.0 per 
million individuals), reliable estimates of the incidence of PCP 
in this population as well as risk-enhancing characteristics and 
PCP-attributable mortality rates are unknown. We report the 
observations on 5 patients with PCP in a cohort of 53 patients 
with Cushing’s syndrome, and our institution serves as a 
national referral center for this disease. The issue of appropriate 
chemoprophylaxis in this patient population is concisely dis-
cussed in conjunction with a systematic review of the literature.
METHODS
All patients diagnosed with Cushing’s syndrome and treated 
between January 1, 2003 and July 1, 2015 were included. Data 
about the cause of Cushing’s syndrome, levels of morning 
serum cortisol, ACTH serum levels, midnight salivary corti-
sol, 24-hour urinary free cortisol excretion (24-h UFC), and 
outcome were obtained from the electronic patient records. 
Pneumocystis pneumonia was regarded as confirmed if clinical 
and radiological findings were suggestive for PCP and a bron-
choalveolar lavage fluid provided microbiological evidence of 
the presence of P jirovecii (by polymerase chain reaction and/
or Giemsa and silver staining). Univariate non-parametric 
tests were performed for comparison of patient characteristics 
and laboratory results between patients with and without PCP. 
Standard PCP chemoprophylaxis was not prescribed. A waiver 
for informed consent and permission for conduct of the study 
was obtained from the institutional review board.
A systematic review of PCP in patients with Cushing’s syn-
drome was conducted using Medline databases (search strat-
egy: see Supplement 2). All articles describing patients with 
Cushing’s syndrome and PCP, for whom at least 1 cortisol 
measurement was reported, were included. Articles were inde-
pendently assessed by 2 of the investigators (K. v. H. and L. V.). 
Of the selected articles, the literature references were reviewed 
to identify potential articles missed by the initial search strategy.
RESULTS
Between January 2003 and July 2015, 53 patients were diag-
nosed with Cushing’s syndrome and they were included in the 
study. The median age was 49 years (range, 15–74 years), and 39 
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(73.6%) patients were female. Common causes of Cushing’s syn-
drome, ie, pituitary micro- and macroadenoma, adrenal gland 
adenoma, or hyperplasia, were present in 46 (87%) patients, and 
7 patients had a malignant and/or ectopic cause of hypercor-
tisolism. Five patients developed PCP after initiation of corti-
sol-lowering therapy. The characteristics of these patients are 
described in Table 1. In 4 of these patients, Cushing’s syndrome 
was caused by an ectopic source of ACTH or CRH production. 
Higher levels of morning serum cortisol, midnight salivary 
cortisol, and 24-h UFC were associated with increased risk for 
development of PCP (P = .02, P = .05, and P = .003, respectively; 
Mann-Whitney U test). Of patients with Cushing’s syndrome, 4 
of 53 patients (7.5%) had a 24-h UFC above 10 000 nmol (>67 
times upper limit of normal [ULN]), all of whom developed 
PCP (see Supplement 1, Figure 1).
The systematic review identified 25 publications, 11 of which 
were excluded because cortisol values were not reported (10 
patients) and/or lack of a confirmed PCP diagnosis (3 patients). 
The 14 included articles reported a total of only 15 patients with 
Cushing’s syndrome and PCP (Table  1). In 13 of 15 patients, 
development of PCP was reported to occur after initiation of 
cortisol blocking therapy. All but 1 patient had ectopic Cushing’s 
syndrome. Twenty-four-hour UFCs were only available in 8 
cases, and, of these, 5 patients had levels above 10 000 nmol/24 
hours. The case fatality rate was high: 11 of 15 patients died. 
If reported, the most common cause of death was respiratory 
insufficiency.
DISCUSSION
A limited number of previous reports indicated that the risk 
for a spectrum of opportunistic infectious diseases in patients 
with Cushing’s syndrome is related to the level of excess cor-
tisol production [10, 11]. In accordance with this biologically 
plausible observation, we found a strong association between 
Table 1. Patients With Pneumocystis Pneumonia and Cushing’s Syndrome
Author (Ref. No.)a Age Sex













Chowdry [15] 48 F ACTH producing NET 2930 45 082 After Autopsy Death(R)
Gabalec [16] 60 F Occult ectopic ACTH secre-
tion (unknown origin)
3150 13 630 After BALF Alive
Gabalec [16] 20 M ACTH producing high-grade 
endocrine carcinoma
>1380 1188 After BALF Alive
Chang [17] 60 M Occult ectopic ACTH secre-
tion (unknown origin)
4365 NA Before Blood (PCR) Death(R)
Arlt [18] 36 M ACTH producing metastatic 
NET of the right kidney
2180 9180 After BALF (IF) Death(R)
Oosterhuis [8] 57 F ACTH producing NET 
pancreas
2371 294 306 After BALF Death
Keenan [9] 26 F Occult ectopic ACTH secre-
tion (unknown origin)
1291 31 000 After BALF Alive
Kim [19] 60 F Occult ectopic ACTH secre-
tion (unknown origin)
2207 NA After BALF (Giemsa stain) Death(R)
Bakker [20] 56 M Occult ectopic ACTH secre-
tion (unknown origin)
5450 51 460 After BALF Death(R)
Collichio [21] 53 M SCLC >1380 NA Afterb BALF (cytology) Death
Russi [22] 23 M Pituitary microadenoma 2759 NA After BALF (IF) Alive
Dimopoulos [23] 49 F SCLC 1766 NA After Autopsy Death(R)
Sieber [24] 66 M Ectopic CRH producing oat 
cell carcinoma of the lung
3200 NA Before Biopsy Death
Fulkerson [25] 38 F ACTH producing thymus 
carcinoma
NA 10 × ULNc After Autopsy (silver stain) Death
Natale [26] 24 M ACTH producing carcinoid 3035 130 × ULNc After BALF (silver stain) Death
This report 70 F Thymic carcinoid 8800 52 934 After BALF (Giemsa + silver stain) Death(R)
This report 29 F Adrenal adenoma 500 57 564 After BALF (PCR) Alive
This report 74 M ACTH producing 
pheochromocytoma
1330 10 238 After BALF (PCR) Alive
This report 61 F SCLC 1600 16 090 After BALF (PCR) Death(R)
This report 36 F Adrenal carcinoma 870 790 After BALF (PCR) Death(R)
Abbreviations: ACTH, adrenocorticotropic hormone; BALF, bronchoalveolar lavage fluid; IF, immune fluorescence; NA, not available; NET, neuroendocrine tumor; PCP, Pneumocystis pneu-
monia; PCR, polymerase chain reaction; (R), as superscript to outcome indicates respiratory failure was reported to cause—or at least contributed to—an adverse outcome; SCLC, small 
cell lung carcinoma; ULN, upper limit of normal.
aReferences of the included articles of the systematic review of the literature.
bTherapy for SCLC was started before PCP symptoms, no direct cortisol-lowering therapy.
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the development of PCP and the degree of exposure to cortisol 
excess (as reflected by 24-h UFC, serum, and midnight salivary 
cortisol levels). In addition, PCP was diagnosed in 1 of 46 (2%) 
patients who had a pituitary or adrenal adenoma versus 4 of 
7 (57%) patients with ectopic Cushing’s syndrome. The former 
patient developed Cushing’s syndrome during pregnancy due 
to an adrenal adenoma, and the cortisol excess as reflected by 
24-h UFC exceeded 50 000  nmol. Within our study popula-
tion, ectopic or malignant neoplasms more frequently caused 
extreme levels of hypercortisolism. In concurrence, but possibly 
influenced by publication bias, the literature review showed that 
malignant and ectopic Cushing’s syndrome patients were over-
represented as patients also diagnosed with PCP. The occult 
nature of these conditions may delay correct diagnosis and 
treatment. This further enhances the cumulative exposure to 
steroid hormones, which probably best defines the individual’s 
risk for development of PCP [12].
The high mortality rate of 60%–65% (study cohort and lit-
erature review, respectively) is of major concern. This exceeds 
reported PCP mortality rates of 10%–40% in populations with 
other underlying conditions, eg, HIV and solid organ trans-
plantation [13]. Several factors may account for this observa-
tion. First, the very low incidence of Cushing’s syndrome may 
cause physicians to be unfamiliar with related infectious com-
plications, delaying diagnosis and treatment of PCP. Second, a 
range of other fatal events is prone to occur in patients with 
severe Cushing’s syndrome. Furthermore, the treatment with 
high-dose steroids in severe cases of PCP may not have the 
maximum reducing effect on mortality because of the already 
maximal decreased sensitivity of immune cells for steroid com-
pounds [14].
It is notable that, in the majority of patients, PCP was 
diagnosed after initiation of cortisol-lowering therapy. The 
systematic review confirmed that PCP often becomes man-
ifest after initiation of treatment for hypercortisolism. This 
strongly suggests that immune reconstitution is an important 
component or even a prerequisite for development of clini-
cally overt PCP in this population. During prolonged hyper-
cortisolism, patients may acquire an ever-accumulating lung 
burden of P jirovecii, whilst the high level of cortisol sup-
presses the inflammatory response. A vigorous inflammatory 
reaction can develop only after an abrupt decrease of cortisol 
levels. Both—but in particular the combination of—a rela-
tively high fungal burden and a sudden reversal of immune 
repression can be expected to negatively impact the outcome 
of PCP.
At present, the management of Cushing’s syndrome does not 
routinely include PCP prophylaxis or preemptive treatment 
[7, 9, 10]. Similar to all antimicrobial chemoprophylaxis, the 
indication of PCP prophylaxis in patients with Cushing’s syn-
drome depends on a harm-benefit analysis. Although larger 
cohorts would provide more reliable estimates, the number 
of patients needed to be treated with chemoprophylaxis to 
prevent 1 PCP case is probably <50. From the available but 
limited data, it can be deduced that the presence of ectopic or 
malignant causes of Cushing’s syndrome as well as extreme 
levels of cortisol (ie, in the 5th percentile, ie, >20 times the 
ULN) point towards a very high risk for development of PCP. 
Taking mortality rates into account, the benefits strongly 
weigh against the limited toxicity and side effects usually 
caused by a prophylactic dosage of trimethoprim-sulfameth-
oxazole (TMP-SMX). The duration of prophylaxis should be 
extended to the time that the effects of hypercortisolism on 
the immune system have waned.
CONCLUSIONS
Due to the very low incidence of Cushing’s syndrome, an 
adequate PCP chemoprophylaxis strategy should now be 
constructed based on the available observational data. Based 
on previous studies and on our own experience, we rec-
ommend PCP chemoprophylaxis for all patients diagnosed 
with Cushing’s syndrome, especially those with high 24-h 
UFCs. As a consequence of the potential role of immune 
reconstitution, a patient with Cushing’s syndrome should 
preferably start PCP chemoprophylaxis before initiation 
of cortisol-lowering therapy. Of note, any delay in optimal 
management of the Cushing’s syndrome should be avoided. 
In addition, with regard to the very high mortality rate of 
PCP in patients with Cushing’s syndrome, either preemptive 
therapy of PCP with high-dose TMP-SMX or chemoprophy-
laxis plus assertive monitoring is indicated for patients with 
an increased risk profile (ectopic Cushing’s syndrome or 
extreme cortisol levels).
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